Psychometric assessment of a modified part I of the unified multiple system atrophy rating scale

IF 2.7 Q3 CLINICAL NEUROLOGY
Clinical Parkinsonism Related Disorders Pub Date : 2026-01-01 Epub Date: 2026-10-13 DOI:10.1016/j.prdoa.2026.100510
Anna-Karin Berger, Andreas Rieckmann, Krishan Nighah, Stefano Zanigni
{"title":"Psychometric assessment of a modified part I of the unified multiple system atrophy rating scale","authors":"Anna-Karin Berger,&nbsp;Andreas Rieckmann,&nbsp;Krishan Nighah,&nbsp;Stefano Zanigni","doi":"10.1016/j.prdoa.2026.100510","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Despite widespread use in MSA clinical trials, the UMSARS has recognized limitations in responsiveness.</div></div><div><h3>Objectives</h3><div>To evaluate the psychometric properties of a modified UMSARS Part I incorporating collapsed response categories (0 and 1) and excluding item 11 (sexual function).</div></div><div><h3>Methods</h3><div>Psychometric properties and responsiveness of the modified UMSARS Part I were assessed and compared with other UMSARS scores using data from a randomized, double-blind, placebo-controlled trial.</div></div><div><h3>Results</h3><div>For the mUMSARS Part I, internal consistency (Cronbach's alpha) was 0.80 at Week 48 and 0.76 at end-of-treatment, and test-retest reliability (intraclass correlation coefficient) was 0.61. Construct validity for mUMSARS Part I ranged from <em>r</em> = 0.51–0.72, comparable to the UMSARS Total score (<em>r</em> = 0.49–0.69) and higher than UMSARS Part I (<em>r</em> = 0.42–0.60). At Week 48, mUMSARS Part I effect sizes across global impression anchors were large in worsening groups (1.64–2.92) and lower in no-change groups (0.97–1.62).</div></div><div><h3>Conclusions</h3><div>The modified scale demonstrates acceptable psychometric properties, supporting its use in trials assessing progression of MSA. Both the original UMSARS Part I and mUMSARS Part I performed well across psychometric assessments; however, the mUMSARS Part I showed consistently stronger construct validity and greater responsiveness to change.</div></div>","PeriodicalId":33691,"journal":{"name":"Clinical Parkinsonism Related Disorders","volume":"15 ","pages":"Article 100510"},"PeriodicalIF":2.7000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Parkinsonism Related Disorders","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590112526000903","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Despite widespread use in MSA clinical trials, the UMSARS has recognized limitations in responsiveness.

Objectives

To evaluate the psychometric properties of a modified UMSARS Part I incorporating collapsed response categories (0 and 1) and excluding item 11 (sexual function).

Methods

Psychometric properties and responsiveness of the modified UMSARS Part I were assessed and compared with other UMSARS scores using data from a randomized, double-blind, placebo-controlled trial.

Results

For the mUMSARS Part I, internal consistency (Cronbach's alpha) was 0.80 at Week 48 and 0.76 at end-of-treatment, and test-retest reliability (intraclass correlation coefficient) was 0.61. Construct validity for mUMSARS Part I ranged from r = 0.51–0.72, comparable to the UMSARS Total score (r = 0.49–0.69) and higher than UMSARS Part I (r = 0.42–0.60). At Week 48, mUMSARS Part I effect sizes across global impression anchors were large in worsening groups (1.64–2.92) and lower in no-change groups (0.97–1.62).

Conclusions

The modified scale demonstrates acceptable psychometric properties, supporting its use in trials assessing progression of MSA. Both the original UMSARS Part I and mUMSARS Part I performed well across psychometric assessments; however, the mUMSARS Part I showed consistently stronger construct validity and greater responsiveness to change.
心理计量学评估统一多系统萎缩评定量表的修改第一部分
尽管在MSA临床试验中广泛使用,但UMSARS在反应性方面存在公认的局限性。目的评价纳入崩溃反应类别(0和1)并排除第11项(性功能)的修改后的UMSARS第一部分的心理测量特性。方法采用随机、双盲、安慰剂对照试验的数据,评估改良UMSARS第一部分的心理计量学特性和反应性,并与其他UMSARS评分进行比较。结果第一部分的内部一致性(Cronbach’s alpha)在48周时为0.80,治疗结束时为0.76,重测信度(类内相关系数)为0.61。mUMSARS第一部分的结构效度r = 0.51-0.72,与UMSARS总分相当(r = 0.49-0.69),高于UMSARS第一部分(r = 0.42-0.60)。在第48周,全球印象锚点的腮腺炎第一部分效应量在恶化组中很大(1.64-2.92),在无变化组中较低(0.97-1.62)。结论改进后的量表具有可接受的心理测量特性,支持其在评估MSA进展的试验中使用。最初的UMSARS第一部分和mUMSARS第一部分在心理测量评估中表现良好;然而,mUMSARS第一部分始终表现出更强的构念效度和对变化的反应性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Parkinsonism  Related Disorders
Clinical Parkinsonism Related Disorders Medicine-Neurology (clinical)
CiteScore
2.70
自引率
0.00%
发文量
50
审稿时长
98 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书